Aug 13, 2026 earnings call — Revenue and margin improvement; FDA clearance and product updates
Second quarter revenue was $1.3 million, a record for any second quarter, with gross margin 64%.
Revenue $0.0B (est $0.0B) · EPS $-12.35 (est $-8.40)
Key quotes
"Second quarter revenue was $1.3 million an increase of 127% over the second quarter last year and gross profit was $800 thousand an increase of 232%."
"Position and distributor training is the leading indicator for us. And on that front, our training events increased 98% in the first half of 26 compared with the second half of 25."
"Second, as it relates to regulatory matters, subsequent to the quarter end, on July 2, we announced that we received FDA 510(k) clearance for the catamaran SI joint fusion system."
Analyst Q&A 1
SiVantage product updates and physician training
Q (Nicholas Sherwood · Maxim): The analyst asked about advancements in the SiVantage product pipeline and how regulatory and R&D work is progressing. He also asked whether there will be special events or pushes to train new physicians through the end of the year.
A: They said the SiVantage SImmetry+ has 3 major components and 1 was already released. The second component is an enhanced accreditation tool that will be out in October for clinical use, and the platform enhancements will roll out over 2 to 6 months. They also said they are finishing testing a novel posterior approach technology and preparing an FDA submission, and that a new training center in Tampa has increased physician training activity in the first half of 26 compared to 25 with continued uptick expected.
"The second is an enhanced accreditation tool, which we mentioned will be out here in October for clinical use." — Steven Foster (CEO)